Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Milnacipran on Pain in Fibromyalgia (Forest)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by University of California, San Diego
Forest Laboratories
Information provided by (Responsible Party):
Tobias Moeller-Bertram, University of California, San Diego Identifier:
First received: February 1, 2011
Last updated: June 24, 2013
Last verified: June 2013

February 1, 2011
June 24, 2013
February 2011
February 2014   (final data collection date for primary outcome measure)
Concentration of norepinephrine in cerebrospinal fluid in response to experiemental pain before and after milnacipran treatment. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
The investigators will measure cerebrospinal fluid norepinephrine levels in response to painful heat stimuli before and after a 12 week course of milnacipran in fibromyalgia patients.
Same as current
Complete list of historical versions of study NCT01288807 on Archive Site
  • Measure sensory thresholds for touch, pressure, and temperature pain [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Investigators will utilize quantitative sensory testing to assess changes in sensory thresholds among patients with fibromyalgia before and after a twelve (12) week course of milnacipran.
  • Measure pain ratings and Fibromyalgia symptoms [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Fibromyalgia patients will be asked to keep a pain diary which assess spontaneous pain ratings daily, a subjective weekly assessment, as well as degree of improvement weekly during treatment period on a numeric rating scale.
  • Measure concentrations of serotonin and substance P cerebrospinal fluid and plasma [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The investigators will measure cerebrospinal fluid and plasma concentrations of serotonin and substance P in CSF and plasma before and after twelve (12) weeks of treatment with milnacipran.
Same as current
Not Provided
Not Provided
Effect of Milnacipran on Pain in Fibromyalgia
Effects of a 12 Week Milnacipran 200 mg Treatment on Pain Perception and Pain Processing in Fibromyalgia - An Open Label Study

The investigators want to study the effects of milnacipran treatment on neurotransmitter release in fibromyalgia.

Fibromyalgia (FM) is a chronic pain condition with significant morbidity. Current research suggests a primarily central mediation of the widespread pain including central sensitization at the spinal level and abnormal pain processing at the cerebral level. Findings in FM patients include abnormal neurotransmitter levels in cerebrospinal fluid (CSF), abnormal activation of cerebral pain processing areas and abnormal peripheral pain and sensory thresholds. Continuous low level spinal cord activation by primary nociceptive afferents (C and A delta fibers) is believed to significantly drive the central sensitization. One major spinal neurotransmitter released by these pain fibers is substance P (SP). Several studies have shown that FM patients have up to three times higher baseline SP levels in the CSF compared to controls. Since spinal neurotransmitter release and therefore nociceptive afferent activity is also regulated via a descending inhibitory pathway releasing norepinephrine (NE) and serotonin (5HT), decreased activity of this pain modulating system could also be involved in abnormal pain processing in FM. Indeed, there is support in the literature for decreased CSF levels of both NE and 5HT or their metabolites. Milnacipran, a NE and 5HT reuptake inhibitor, has been shown to potentially effectively reduce FM pain and symptoms of FM by affecting the above pathologies.

The investigators propose an open label clinical trial with milnacipran 200 mg over 12-weeks in order to investigate the pain pathway in FM patients at peripheral and spinal levels before and after treatment. In addition, the investigators will assess pain intensity and symptoms of FM before, during and after treatment. To determine if there are peripheral effects, the investigators will characterize the systemic neurotransmitter release and their metabolites in plasma. The investigators will also measure the heart rate variability using an electrocardiogram to look for effects on the sympathetic nervous system.

Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Drug: Milnacipram
Titration to 200mg PO daily
Experimental: Treatment
Titrated Milnacipram doses
Intervention: Drug: Milnacipram
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female age 18 or older
  • Written informed consent and written release of health and research study information
  • Diagnosis of Fibromyalgia
  • Participant has pain greater than 4 on the NRS of 0 to 10 on average over the last week prior to initial evaluation that interferes with function most days per week
  • Pain duration greater than 6 months
  • Negative urine pregnancy test on experimental day 1 and 2 and on first day of treatment prior to administration of study medication and fluoroscopy
  • Ability to speak and understand English, to follow instructions, and fill out study questionnaires
  • Likely to complete all required visits
  • Must be ambulatory and able to lay prone for 30 minutes

Exclusion Criteria:

  • Any condition or situation that in the investigator's opinion may put the participant at significant risk, confound the study results, or interfere significantly with the participant's participation in the study
  • Serious, unstable medical illness that could lead to hospitalization over the next three months; and/or a DSM-IV diagnosis(es) with active problems within the last six months, such as: schizophrenia, bipolar disorder, antisocial personality disorder, or substance use disorder
  • Known, uncontrolled, serious systemic disease, including: hypertension and/or tachyarrythmia
  • Females who are pregnant, breast feeding, or who plan to become pregnant, or who may potentially become pregnant
  • Allergy or sensitivity to any component of the study medication or to contrast dye
  • Patients on coumadin, heparin, or any other known increase risk of bleeding
  • Signs of increased intracranial pressure
  • Patients who are unable to continue current pain medication
  • Allergy or contraindication to acetaminophen
  • Use of monoamine oxidase inhibitors
  • Uncontrolled narrow-angle glaucoma
18 Years and older
Contact: Meegin Kincaid, B.S. 858-552-8585 ext 2386
Contact: Leng Ky, M.D. 858-552-8585 ext 2386
United States
Tobias Moeller-Bertram, University of California, San Diego
University of California, San Diego
  • Forest Laboratories
  • Department of Veterans Affairs
Principal Investigator: Tobias Moeller-Bertram, MD, PhD, MAS University of California, San Diego
University of California, San Diego
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP